Featured Posts

Wednesday, February 6, 2019

Lactobacillus brevisCD2 may delay gingivitis development in this model by downregulating an inflammatory cascade.

PMID:  Oral Dis. 2015 Sep ;21(6):705-12. Epub 2015 Apr 20. PMID: 25720615 Abstract Title:  Modulation of the host response by probiotic Lactobacillus brevis CD2 in experimental gingivitis. Abstract:  OBJECTIVE: Probiotic Lactobacillus brevisCD2 (CD2) exerts anti-inflammatory properties by preventing nitric oxide synthesis. It is hypothesized that oral application of CD2 can inhibit naturally occurring gingival inflammation.MATERIALS AND METHODS: Thirty-four healthy adults were randomized to receive L. brevisCD2 lozenges or placebo, three times daily for 14 days. The subjects refrained from oral hygiene, the extent of which was determined at various time points.RESULTS: In both groups, bleeding on probing scores increased continuously throughout the study except on day 3. In the placebo group, scores increased significantly from 9.50 at baseline to 14.75 and 14.81 on days 10 and 14, respectively (P

read more



from GreenMedInfo http://bit.ly/2Sr4xyT

No comments:

Post a Comment